7/21/2009 | SS | SEC slaps Perry Corp. with $150,000 fine for violating securities law
|
9/26/2008 | SP | New Issue: Barclays prices $3 million 14.75% reverse convertibles linked to Mylan Laboratories
|
9/12/2008 | SP | Barclays to price 14.75% reverse convertibles linked to Mylan Laboratories
|
8/29/2008 | CV | Market Commentary: Mylan, Medtronic trade flat to lower; Ambac gives back some gains; energy names quiet despite storm
|
8/28/2008 | SP | New Issue: Barclays prices $3.5 million 13.8% reverse convertibles linked to Mylan Laboratories
|
8/13/2008 | SP | Barclays to price 13.8% reverse convertibles linked to Mylan Laboratories
|
5/29/2008 | SP | New Issue: Barclays prices $5 million 13% reverse convertibles linked to Mylan Laboratories
|
5/9/2008 | SP | Barclays to price 13% reverse convertibles linked to Mylan
|
4/9/2008 | SP | Barclays to price 10.75% reverse convertibles linked to Mylan Labs
|
3/11/2008 | SP | Barclays to price 10.25% reverse convertibles linked to Mylan
|
2/11/2008 | SP | Barclays to price 12.5% reverse convertibles linked to Mylan
|
12/10/2007 | SP | Barclays to price 16.25% reverse convertibles linked to Mylan
|
11/8/2007 | SP | Barclays to price 13% reverse convertibles linked to Mylan Laboratories
|
10/30/2007 | SP | New Issue: Barclays prices $1.5 million 13.5% reverse convertibles linked to Mylan Laboratories
|
10/29/2007 | SP | New Issue: Barclays prices $2 million 12.25% reverse convertibles linked to Mylan Laboratories
|
10/24/2007 | SP | Market Commentary: Reverse convertibles 'great product for right customer,' market insider says; Barclays plans deals
|
10/24/2007 | SP | Barclays to price 12.25% reverse convertibles linked to Mylan
|
10/10/2007 | SP | Barclays to price 13.5% reverse convertibles linked to Mylan
|
10/5/2007 | BKHY | Mylan Laboratories gets $4.85 billion facility; $2.85 billion interim facility
|
10/4/2007 | CV | Market Commentary: Intel, Micron recover; AMD moves up; Excel Maritime sets sail higher; Molina Healthcare eagerly anticipated
|
10/2/2007 | SS | Mylan completes acquisition of Merck Generics
|
9/28/2007 | HY | Mylan extends tender offers for 53/4%, 6 3/8% notes
|
9/27/2007 | SP | New Issue: Barclays prices $3.5 million 13% reverse convertibles linked to Mylan Laboratories
|
9/27/2007 | SP | New Issue: RBC sells $84,000 10.5% reverse convertibles linked to Mylan Laboratories
|
9/17/2007 | HY | Mylan prices tender offers for 53/4%, 6 3/8% notes
|
9/10/2007 | SP | RBC to price 10.5% reverse convertibles linked to Mylan
|
8/31/2007 | HY | Mylan begins tender offers, consent solicitations for 53/4%, 6 3/8% notes
|
7/26/2007 | SP | New Issue: Barclays prices $2 million 9.25% reverse convertibles linked to Mylan Laboratories
|
7/11/2007 | CV | Market Commentary: Newmont seen coming tight; Kendle, SonoSite active, CVRD moves higher again
|
7/10/2007 | SP | Barclays to price 9.25% reverse convertibles linked to Mylan
|
7/10/2007 | CV | Market Commentary: Kendle, SonoSite talked cheap; Live Nation questioned; Medtronic, Mylan seen safe in choppy market
|
5/17/2007 | BKHY | Mylan acquisition financing to include $4.85 billion facility, $2.85 billion bonds
|
5/16/2007 | SP | New Issue: ABN Amro sells $2 million 11.75% Knock-in Reverse Exchangeables linked to Mylan
|
5/14/2007 | SS | Mylan Laboratories to acquire Merck Generics for $6.7 billion in cash
|
5/14/2007 | SS | Market Commentary: DaimlerChrysler up; Magna off; Ford flies; Cleveland-Cliffs up; Mosaic higher; Teva advances
|
5/14/2007 | BKCVHY | Mylan plans new bank debt, bonds for purchase of Merck's generics business
|
5/14/2007 | BKCVHY | S&P lowers Mylan
|
5/14/2007 | BKCVHY | Moody's may downgrade Mylan
|
5/14/2007 | CV | Market Commentary: Mylan falls on acquisition; Ford gains on Chrysler deal, buyout hopes; Gold Reserve reserved in gray
|
3/2/2007 | CV | Market Commentary: Mylan, Hospitality Properties climb on debut; Health Management, Superior Energy gain with stocks
|
3/2/2007 | CV | New Issue: Mylan prices upsized $550 million five-year convertibles at rich end, at 1.25%, up 15%
|
2/21/2007 | BK | Mylan plans $750 million of new bank debt
|
2/21/2007 | BKCVHY | Moody's rates Mylan loans Ba1
|
2/20/2007 | CV | Mylan to price $400 million five-year convertibles March 1, talked at 1.25%-1.75%, up 10%-15%
|
2/20/2007 | CV | Market Commentary: XM jumps on merger amid put debate; Charys sneaks into secondary market; Mylan deal gets early nods
|
2/20/2007 | CVHY | Mylan Laboratories files automatic shelf registration
|
11/1/2006 | BT | Mylan second-quarter earnings per share rise to $0.37 from $0.22 year ago
|
9/21/2006 | BKBTCVHY | Moody's revises ratings for nine U.S. pharma companies
|
9/12/2006 | BT | Mylan gets FDA approval for generic Topamax
|
9/7/2006 | BT | Mylan: court upholds patent decision in favor of Oxybutynin products
|
8/30/2006 | BKBTHY | Moody's affirms Mylan
|
8/30/2006 | BT | Mylan: FDA tentatively approves generic Sarafem Pulvules Capsules for premenstrual disorder
|
8/28/2006 | BK | Mylan to draw on revolver for purchase of controlling interest in Matrix
|
8/28/2006 | BKBT | S&P affirms Mylan Laboratories
|
8/28/2006 | BT | Mylan to acquire up to 71.5% interest in Matrix for $736 million
|
8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
8/14/2006 | BT | Mylan's Venlafaxine hydrochloride tablets get FDA tentative approval
|
8/7/2006 | BT | Mylan says FDA approvals for generic transdermal fentanyl no longer expected in 2007
|
8/2/2006 | BT | Daiichi Sankyo units file patent infringement suit against Mylan for Benicar
|
7/26/2006 | BT | Mylan first-quarter net revenues up 9% at $348.8 million
|
7/26/2006 | BT | Mylan gets patent covering transdermal drug Emsam to treat depressive disorder
|
7/26/2006 | BKBT | Mylan gets $700 million unsecured revolver
|
7/25/2006 | BT | Mylan to market generic Climara
|
7/20/2006 | BT | Mylan, Glenmark, Cadila, Teva to sell generic Mobic for osteoarthritis
|
7/13/2006 | BT | Mylan's generic version of Novartis' Lotrel for hypertension approved by FDA
|
7/6/2006 | BKBTHY | S&P gives Mylan Laboratories loan BBB-
|
6/30/2006 | BKBTHY | Moody's rates Mylan loan Ba1
|
5/24/2006 | BT | FDA tentatively approves Mylan's generic form of Imitrex for migraines
|
4/25/2006 | BT | FDA approves Mylan's generic Cilostazol Tablets
|
4/18/2006 | BT | Mylan announces tentative approval for Finasteride tablets
|
4/12/2006 | BT | Mylan receives tentative FDA approval of ANDA for generic Allegra
|
2/24/2006 | BT | Citigroup reiterates Mylan at buy
|
2/23/2006 | BT | Mylan announces tentative approval for Carvedilol tablets
|
2/6/2006 | BT | Mylan: FDA approves cyclobenzaprine hydrochloride, generic of Flexeril
|
2/3/2006 | BT | Citigroup reiterates Mylan at buy
|
2/2/2006 | BT | Citigroup reiterates Mylan at buy
|
1/27/2006 | BT | Mylan receives final FDA OK for Alprazolam Extended-release Tablets
|
1/19/2006 | BT | Mylan receives tentative FDA approval for generic acid reflux tablets
|
1/11/2006 | BT | Mylan, Cephalon form agreements for pain, CNS disorder drugs
|
1/11/2006 | BT | Mylan licenses nebivolol to Forest, to receive $75 million and milestones
|
1/10/2006 | BT | Cephalon settles patent litigation with Mylan over Provigil generic
|
12/23/2005 | BT | Mylan, Barr get final FDA approval for Zonisamide, generic of Zonegran to treat epilepsy
|
12/22/2005 | BT | Daiichi says appeals court upholds decision against allowing Mylan's generic levofloxacin
|
12/20/2005 | BT | Mylan reaches oxybutynin supply agreement with Ortho-McNeil, Alza
|
12/19/2005 | BT | Mylan receives final FDA approval for generic blood pressure tablets
|
11/29/2005 | BT | Mylan gets FDA OK for Glimepiride, a generic of blood-sugar lowering Amaryl for Type 2 diabetes
|
11/4/2005 | BT | Mylan sells rights of Parkinson's disease treatment Apokyn to Vernalis
|
11/4/2005 | BT | Citigroup starts Mylan Labs coverage with buy rating
|
10/27/2005 | BT | Mylan reports positive FDA committee development on Emsam
|
10/20/2005 | BT | Market Commentary: Predix IPO put on hold; Amgen spiral continues; Abgenix climbs; generics off despite Tamiflu talks
|
8/17/2005 | HY | Market Commentary: Some telecom, healthcare names seen moving on news; Syniverse talk emerges
|
7/26/2005 | BT | Market Commentary: Glaxo pact helps Human Genome; Mylan, Impax up with Teva, Ivax; Elan, Biogen up on Tysabri plans
|
7/22/2005 | BK | Market Commentary: UTGR price talk emerges; Key Energy cuts institutional spreads, adds soft call
|
7/19/2005 | BT | Market Commentary: Able bankruptcy sparks buying by restructuring specialists; Amgen a blowout; Genentech weighs on QLT
|
7/19/2005 | BT | S&P: U.S. generic drug industry entering more challenging period; Alpharma, Mylan, Teva, Watson at risk
|
7/19/2005 | HY | Market Commentary: Ford debt little moved on lower earnings; National Waterworks gains on buyout plan; Acco seen launching
|
7/18/2005 | BK | Market Commentary: Allegheny Energy Supply, Mylan break for trading; MotorCity adds new tranche, cuts institutional spread
|
7/18/2005 | BT | Mylan tender for stock oversubscribed at $19.50, exercises option to buy 2% more
|
7/15/2005 | HY | Market Commentary: Dura Automotive up after stock upgrade; Central European Distribution prices upsized deal
|
7/14/2005 | BT | Market Commentary: Genentech active; CryoCor IPO trades up, sinks; Mylan prices tight, center; BioMarin off on follow-on
|
7/14/2005 | HY | Market Commentary: Mylan Labs, several upsized deals price; auto sector better; funds see $12 million outflow
|
7/14/2005 | BTHY | New Issue: Mylan prices $150 million 5-year notes to yield 53/4%, $350 million 10-year notes to yield 6 3/8%
|
7/13/2005 | BTHY | Mylan talks $500 million note deal: five-year bullet at 5 7/8% area, 10-year notes at 6 3/8% area
|
7/13/2005 | BT | Market Commentary: Genentech floats $2 billion in bonds; Advanced Medical Optics convert dished up; Mylan talk out
|
7/13/2005 | HY | Market Commentary: Bally eases as it seeks waiver extension; Scheider Moebel deal pulled, Quiksilver upsizes
|
7/11/2005 | BT | Market Commentary: Accentia runs into resistance; Canadian biotechs tap PIPEs; eyes on Genentech; Mylan up
|
7/11/2005 | HY | Market Commentary: US Unwired gains on Sprint buyout offer; Iesy euro/dollar deal prices
|
7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
7/6/2005 | BT | Market Commentary: Adams Respiratory sets IPO price; Accentia, Advanced Life Sciences seen on deck; Amgen issues higher
|
7/5/2005 | BT | Market Commentary: Voyager plans IPO; Able Labs plunges; Mylan Labs launch seen; Boston Scientific up, J&J lower
|
7/5/2005 | HY | Market Commentary: Autos seen perhaps a little higher as Ford, Chrysler match GM incentives; Cirsa deal prices
|
7/5/2005 | BTHY | Mylan Laboratories to start roadshow Wednesday for $500 million two-part deal
|
7/1/2005 | BT | Market Commentary: Altana crushed by Pfizer news; Cubist, Corixa rise in thin market, Millennium off; Cephalon higher
|
6/30/2005 | BT | Market Commentary: Elan shares move up, credit lags, Connetics rises against the tide; Medicis, Inamed up; Millipore off
|
6/30/2005 | BK | Market Commentary: Acco sets talk; EnviroSolutions upsizes, cuts spread; Magellan, Coffeyville, Hercules break for trading
|
6/23/2005 | BT | Market Commentary: Forest Labs up sharply; King sees buying; Avalon sets IPO range; Salix dives; Xoma, ViaCell bounce
|
6/21/2005 | BKBTHY | Moody's gives Mylan loans, notes Ba1
|
6/21/2005 | BT | Market Commentary: Critical Therapeutics zooms after financing round; Mylan launches bank facility; Eyetech seen higher
|
6/21/2005 | BKBT | Mylan launches $475 million credit facility
|
6/17/2005 | BKBTHY | S&P rates Mylan notes BB+, loan BBB-
|
6/17/2005 | BT | Market Commentary: Mylan Labs bond deal surfaces; Vertex up, Merck lags; Genentech rises; stem cell names watched
|
6/17/2005 | BKBT | Mylan plans $475 million credit facility for common stock Dutch auction
|
6/17/2005 | HY | Market Commentary: Northwest falls as fare hike fails; Mylan, Chaparral Steel, others slate deals
|
6/17/2005 | BTHY | Mylan Laboratories to sell $500 million 10-year notes via Merrill
|
6/16/2005 | BT | Mylan Laboratories commences tender for up to 48.8 million shares
|
6/15/2005 | BT | Market Commentary: Mylan leveling off; ev3 seen in trouble, Micrus prices below range; Invitrogen up; ID Biomed eyed
|
6/15/2005 | BT | Mylan Labs upgraded by Lehman
|
6/14/2005 | BKBT | S&P rates Mylan BBB-
|
6/14/2005 | BT | Mylan Laboratories announces $1.25 billion share buyback, licensing for blood pressure drug
|
6/14/2005 | BT | Market Commentary: Mylan tops biotech activity with big stock buyback; King issues eyed; Invitrogen convertible on tap
|
6/14/2005 | BK | Mylan Laboratories plans $975 million credit facility
|
6/14/2005 | BKBT | Moody's assigns Mylan Ba1
|